How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,128 results for

Child Safety Seat

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis (ESPRIT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02178306

2014 Clinical Trials

102. 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2014 Clinical Trials

103. Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg. Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well (...) Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2014 Clinical Trials

104. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2014 Clinical Trials

105. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning (...) You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2014 Clinical Trials

106. A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients

A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2014 Clinical Trials

107. Association between child restraint systems use and injury in motor vehicle crashes. (PubMed)

] = 2.40 to 16.48). Restrained children aged 4 to 7 years in rear seats with seat belts only (OR = 0.33, 95% CI = 0.11 to 0.94) and infants in front seats using child safety seats (OR = 0.26, 95% CI = 0.07 to 0.99) were associated with decreased nonfatal but not fatal injury compared to children with the recommended use of CRS in the two age groups.Failure to use child restraints was associated with increased fatal injury. Our findings raise questions regarding current recommendations for specific CRS (...) Association between child restraint systems use and injury in motor vehicle crashes. The objective was to estimate the fatal and nonfatal injury risk associated with inappropriate or no use of child restraint systems (CRS) for children younger than 13 years of age involved in motor vehicle crashes (MVC) in the United States.This was a cross-sectional study of children aged 0 to 12 years involved in MVCs based on a nationally representative probability sample from 1996 to 2005 in the United

Full Text available with Trip Pro

2012 Academic Emergency Medicine

108. The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?

× Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage? (LINIPOCHE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been (...) The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage? The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2012 Clinical Trials

109. Prevention of child injuries during tornadoes: cases from the 2011 tornado outbreak in alabama. (PubMed)

directly exposed to a violent tornado (Enhanced Fujita Scale 4) were using safety equipment, specifically, a helmet and infant car seats. These 3 children sustained only minor injuries.Personal protective devices may have played a role in preventing child injuries from tornadoes. To our knowledge, this is the first report in the medical literature on helmet and infant car seat use as child protective devices during tornadoes. (...) Prevention of child injuries during tornadoes: cases from the 2011 tornado outbreak in alabama. Tornadoes and violent weather pose a hazard to children, yet little is known about the use of personal protective devices during storms. An outbreak of tornadoes on April 27, 2011, resulted in the deaths of 23 children in Alabama.Records from 60 patients seen in a pediatric emergency department for tornado-related injuries were reviewed to identify the use of injury prevention devices.Three children

2012 Pediatric Emergency Care

110. Association between weight and risk of crash-related injuries for children in child restraints. (PubMed)

significant injuries.The National Automotive Sampling System Crashworthiness Data System study sample included 650 children 1 to 5 years of age in forward-facing child restraints who weighed 20 to 65 lb and 344 children 3 to 8 years of age in belt-positioning booster seats who weighed 30 to 100 lb. With adjustment for seating position, type of vehicle, direction of impact, crash severity, and vehicle model year, there was no association between absolute weight and clinically significant injuries in either (...) age group (odds ratio: 1.17 [95% confidence interval: 0.96-1.42] for children 1-5 years of age in forward-facing child restraints and 1.22 [95% confidence interval: 0.96-1.55] for children 3-8 years of age in belt-positioning booster seats).The risk of clinically significant injuries was not associated with weight across a broad weight range in this sample of children in MVCs who were using child restraint systems. Parents should continue to restrain their children according to current

2011 Pediatrics

111. Using the pediatric emergency department to deliver tailored safety messages: results of a randomized controlled trial. (PubMed)

Using the pediatric emergency department to deliver tailored safety messages: results of a randomized controlled trial. This study aimed to evaluate the impact of a computer kiosk intervention on parents' self-reported safety knowledge as well as observed child safety seat, smoke alarm use, and safe poison storage and to compare self-reported versus observed behaviors.A randomized controlled trial with 720 parents of young children (4 months to 5 years) was conducted in the pediatric emergency (...) the intervention and control groups.The intervention group had significantly higher smoke alarm (82% vs. 78%) and poison storage (83% vs 78%) knowledge scores. The intervention group was more likely to report correct child safety seat use (odds ratio, 1.36; 95% confidence interval, 1.05-1.77; P = 0.02). Observed safety behaviors were lower than self-reported use for both groups. No differences were found between groups for positive or negative predictive values.These results add to the limited literature

Full Text available with Trip Pro

2013 Pediatric Emergency Care

112. Using the pediatric emergency department to deliver tailored safety messages: results of a randomized controlled trial. (PubMed)

Using the pediatric emergency department to deliver tailored safety messages: results of a randomized controlled trial. This study aimed to evaluate the impact of a computer kiosk intervention on parents' self-reported safety knowledge as well as observed child safety seat, smoke alarm use, and safe poison storage and to compare self-reported versus observed behaviors.A randomized controlled trial with 720 parents of young children (4 months to 5 years) was conducted in the pediatric emergency (...) the intervention and control groups.The intervention group had significantly higher smoke alarm (82% vs. 78%) and poison storage (83% vs 78%) knowledge scores. The intervention group was more likely to report correct child safety seat use (odds ratio, 1.36; 95% confidence interval, 1.05-1.77; P = 0.02). Observed safety behaviors were lower than self-reported use for both groups. No differences were found between groups for positive or negative predictive values.These results add to the limited literature

Full Text available with Trip Pro

2013 Pediatric Emergency Care

113. Activities of the Bloomberg Philanthropies Global Road Safety Programme (formerly RS10) in Russia: promising results from a sub-national project. (PubMed)

Activities of the Bloomberg Philanthropies Global Road Safety Programme (formerly RS10) in Russia: promising results from a sub-national project. In Russia, the high Road Traffic Injuries (RTIs) rate has been attributed to two well-known risk factors - the low rates of seatbelt and child restraints use and speeding. Despite the importance of understanding both speeding and seatbelt use patterns for the purpose of direct interventions or monitoring road safety situation, no study has assessed (...) the current status of speeding among all vehicles and seatbelt wearing rates among all vehicle occupants in Russia. We are aware that alcohol is a known risk factor for RTI in the country however the work focused on seat belts and speed. This research was conducted as part of the Bloomberg Philanthropies Global Road Safety Programme and focuses on observed speeding and seatbelt use in two Russian regions: Lipetskaya and Ivanovskaya Oblast.Data was collected through observational surveys on selected roads

2013 Injury

114. Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01602341 Recruitment Status : Completed First Posted : May 21, 2012 Results First Posted : March 6, 2017 Last Update Posted : March 6

2012 Clinical Trials

115. Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

information, Layout table for eligibility information Ages Eligible for Study: 8 Years to 75 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Biopsy-proven primary FSGS (Primary FSGS confirmed by renal biopsy report) OR documentation of a genetic mutation in a podocyte protein associated with the disease. Urine protein/creatinine ratio (Up/C) at or above 1.0 g/g. Estimated glomerular filtration rate (eGFR) >30. Mean seated blood (...) Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2012 Clinical Trials

116. Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01652885 Recruitment Status : Completed First Posted : July 30, 2012 Results First Posted : April 24, 2017 Last Update Posted : April 24, 2017 Sponsor: Pfizer Information

2012 Clinical Trials

117. Safety Study of Albuterol Spiromax® in Subjects With Asthma

Safety Study of Albuterol Spiromax® in Subjects With Asthma Safety Study of Albuterol Spiromax® in Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety Study of Albuterol Spiromax® (...) in Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01698320 Recruitment Status : Completed First Posted : October 3, 2012 Results First Posted : August 19, 2015 Last Update Posted : August 19, 2015 Sponsor: Teva Pharmaceutical Industries Information provided by (Responsible Party

2012 Clinical Trials

118. Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01668654 Recruitment Status

2012 Clinical Trials

119. Practices, Attitudes and Perceptions Toward Road Safety in Yerevan, Republic of Armenia (PubMed)

traffic safety.: In the initial survey, of 2137 numbers dialed, 436 persons were reached and 390 (90%) agreed to participate. Of survey respondents, 90% percent of household cars had seatbelts, while 47% had airbags. Twenty-four percent always or usually wore a seatbelt when driving, 21% wore a belt as a passenger. 39% were unaware of child restraints. Of the 61% who were aware of child restraints, only 32% had ever used one. A follow-up survey was conducted one year later after enforcement efforts (...) were increased. In the follow-up survey, 81% percent always or usually wore a seatbelt when driving, and 69% wore a belt as a passenger. There was no significant increase of awareness or use of child restraints in the follow-up survey.: Although cars in Yerevan have seat belts, the majority of drivers and passengers prior to the intervention did not use them. Knowledge and use of child restraints was poor. The follow-up survey conducted after an enforcement campaign was underway in Yerevan showed

Full Text available with Trip Pro

2012 Annals of Advances in Automotive Medicine / Annual Scientific Conference

120. Adult Safety Belt

Vehicles 2015 Data III. Technique: Correct fitting of adult auto safety belts Use if adult belt does not fit Indications Weighs more than 80 pounds (36 kg) Child standing height over 57 inches (145 cm) Child over 29 inches (74 cm) Proper fit Legs bend over edge of seat Buttocks firmly placed against seat back Lap belt fits tightly over upper thighs belt crosses mid-clavicle and mid- Never use without belt Risk of child submarining under Lap belt IV. Technique: Children See s Children <13 years old (...) Safety Belt , Seat Belt , Car Restraint , Unrestrained Passenger , Seat Belt Use in Pregnancy , Lap belt , Air Bag From Related Chapters II. Epidemiology Seat Belts reduce risk of MVA related deaths in teens and adults by 50% Of fatal U.S. MVAs in 2015, >50% of deceased teens were unrestrained Children ages 4 to 7 years old are prematurely transitioned to Seat Belts in 25% of cases These children should instead be transitioned to s first References (2017) NHTSA Occupant Protection in Passenger

2015 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>